NCT06277635

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases, a Double-blind Randomized Controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Phramongkutklao College of Medicine and Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To study the effect of silymarin against methotrexate-induced liver injury in rheumatic diseases including rheumatoid arthritis, psoriatric arthritis and psoriasis

Detailed description

\- Methotrexate was indeed a common and effective treatment for rheumatoid arthritis, psoriatic arthritis and psoriasis. Methotrexate-related hepatotoxicity are common occur 1:1,100 persons. Liver abnormalities varies from asymptomatic liver enzyme elevation to fatal hepatic necrosis and liver fibrosis. Methotrexate was discontinued owing to liver dysfunction in 7.4%

Conditions

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Psoriasis

Interventions

Type	Name	Description
DRUG	Silymarin	Silymarin is randomly assigned to the participants for 12 weeks during study.
DRUG	Placebo	Placebo is randomly assigned to the participants for 12 weeks during study.

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-04-01
• Completion: 2025-04-01
• First posted: 2024-02-26
• Last updated: 2024-02-26

Locations

1 site across 1 country: Thailand